Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 418

1.

[Progress of anticoagulation therapy in atrial fibrillation.]

Hernández Olmedo M, Suárez Fernández C.

Med Clin (Barc). 2014 Sep 2. pii: S0025-7753(14)00569-7. doi: 10.1016/j.medcli.2014.07.018. [Epub ahead of print] Review. Spanish.

PMID:
25192579
[PubMed - as supplied by publisher]
2.

Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials.

Vanassche T, Hirsh J, Eikelboom JW, Ginsberg JS.

Thromb Haemost. 2014 Sep 4;112(6). [Epub ahead of print]

PMID:
25187203
[PubMed - as supplied by publisher]
3.

[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].

[No authors listed]

Kardiologiia. 2014;54(7):43-52. Russian.

PMID:
25177813
[PubMed - in process]
4.

Anticoagulant-related gastrointestinal bleeding-could this facilitate early detection of benign or malignant gastrointestinal lesions?

Clemens A, Strack A, Noack H, Konstantinides S, Brueckmann M, Lip GY.

Ann Med. 2014 Aug 31:1-7. [Epub ahead of print]

PMID:
25174259
[PubMed - as supplied by publisher]
5.

Anticoagulation Strategies for the Management of Postoperative Atrial Fibrillation.

Anderson E, Dyke C, Levy JH.

Clin Lab Med. 2014 Sep;34(3):537-561. doi: 10.1016/j.cll.2014.06.012. Epub 2014 Jul 19. Review.

PMID:
25168941
[PubMed - as supplied by publisher]
6.

[Appropriate administration of anticoagulants and antiplatelets].

Wakisaka K, Yasaka M.

Nihon Rinsho. 2014 Jul;72(7):1258-63. Japanese.

PMID:
25163318
[PubMed - in process]
7.

Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial.

Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM; for the ROCKET AF Steering Committee & Investigators.

Eur Heart J. 2014 Aug 22. pii: ehu305. [Epub ahead of print]

PMID:
25148838
[PubMed - as supplied by publisher]
8.

Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants.

Ng KH, Hart RG, Eikelboom JW.

Cardiol Ther. 2013 Dec;2(2):135-49. doi: 10.1007/s40119-013-0019-y. Epub 2013 Aug 6.

PMID:
25135392
[PubMed]
Free PMC Article
9.

Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.

Amin A, Stokes M, Makenbaeva D, Wiederkehr D, Wu N, Lawrence JH.

J Med Econ. 2014 Aug 26:1-11. [Epub ahead of print]

PMID:
25133458
[PubMed - as supplied by publisher]
10.

Anti-thrombotic therapy in patients with atrial fibrillation and intracranial hemorrhage.

Diener HC, Stanford S, Abdul-Rahim A, Christensen L, Hougaard KD, Bakhai A, Veltkamp R, Worthmann H.

Expert Rev Neurother. 2014 Sep;14(9):1019-28. doi: 10.1586/14737175.2014.945435. Epub 2014 Aug 4.

PMID:
25091395
[PubMed - in process]
11.

Emergency reversal of vitamin-K antagonists related over-anticoagulation: case report and brief overview on the role of prothrombin complex concentrate.

Di Fusco SA, Aspromonte N, Aquilani S, Mele L, Colivicchi F.

Monaldi Arch Chest Dis. 2013 Dec;80(4):184-8. Review.

PMID:
25087295
[PubMed - indexed for MEDLINE]
12.

Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin.

Hagii J, Tomita H, Metoki N, Saito S, Shiroto H, Hitomi H, Kamada T, Seino S, Takahashi K, Baba Y, Sasaki S, Uchizawa T, Iwata M, Matsumoto S, Osanai T, Yasujima M, Okumura K.

Stroke. 2014 Sep;45(9):2805-7. doi: 10.1161/STROKEAHA.114.006661. Epub 2014 Jul 31.

PMID:
25082810
[PubMed - in process]
13.

Outcome following intracranial hemorrhage associated with novel oral anticoagulants.

Kasliwal MK, Panos NG, Munoz LF, Moftakhar R, Lopes DK, Byrne RW.

J Clin Neurosci. 2014 Jul 24. pii: S0967-5868(14)00321-X. doi: 10.1016/j.jocn.2014.04.025. [Epub ahead of print]

PMID:
25065949
[PubMed - as supplied by publisher]
14.

Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin.

Alonso A, Bengtson LG, MacLehose RF, Lutsey PL, Chen LY, Lakshminarayan K.

Stroke. 2014 Aug;45(8):2286-91. doi: 10.1161/STROKEAHA.114.006016. Epub 2014 Jul 3.

PMID:
24994722
[PubMed - in process]
15.

Comparing mortality in patients with atrial fibrillation who are receiving a direct-acting oral anticoagulant or warfarin: a meta-analysis of randomized trials.

Liew A, O'Donnell M, Douketis J.

J Thromb Haemost. 2014 Sep;12(9):1419-24. doi: 10.1111/jth.12651. Epub 2014 Jul 25.

PMID:
24986568
[PubMed - in process]
16.

[Current management of antithrombotic treatment in patients with non valvular atrial fibrillation and prior history of stroke or transient ischemic attack].

Masjuán J, Álvarez-Sabín J, Blanco M, de Felipe A, Gil-Núñez A, Gállego-Culleré J, Vivancos J.

Rev Neurol. 2014 Jul 1;59(1):25-36. Spanish.

PMID:
24965928
[PubMed - in process]
Free Article
17.

New oral anticoagulants may be particularly useful for asian stroke patients.

Bang OY, Hong KS, Heo JH, Koo J, Kwon SU, Yu KH, Bae HJ, Lee BC, Yoon BW, Kim JS.

J Stroke. 2014 May;16(2):73-80. doi: 10.5853/jos.2014.16.2.73. Epub 2014 May 30. Review.

PMID:
24949312
[PubMed]
Free PMC Article
18.

[Gastrointestinal bleeding under treatment with new oral anticoagulants].

Konturek P, Hess T.

MMW Fortschr Med. 2014 Feb 6;156(2):50-2. Review. German. No abstract available.

PMID:
24934056
[PubMed - indexed for MEDLINE]
19.

Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria.

Clemens A, Noack H, Brueckmann M, Lip GY.

PLoS One. 2014 Jun 9;9(6):e99276. doi: 10.1371/journal.pone.0099276. eCollection 2014.

PMID:
24911432
[PubMed - in process]
Free PMC Article
20.

Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).

Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA; ROCKET AF Steering Committee and Investigators.

Circulation. 2014 Jul 8;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008. Epub 2014 Jun 3.

PMID:
24895454
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk